We chose as a model system the NTERA2 teratocarcinoma cell line, as vesicle producing cells, in which CRIPTO was originally identified and is strongly expressed, and the U87 GBM cells as target cells to use in functional assays. This evidence concerns the gene CRIPTO and glioblastoma.